Regulatory updates, market analysis, and sourcing insights for the peptide supply chain.
The partnership connects peptide businesses with supplier discovery, fulfillment, cold-chain-aware logistics, and white-label infrastructure.
Read ArticleHHS Secretary Robert F. Kennedy Jr. announced a key regulatory change that could open doors for the peptide industry.
Read ArticleCordenPharma acquires AmbioPharm adding facilities in South Carolina and Shanghai, expanding peptide API manufacturing across three continents.
Read ArticleFDA expands Import Alert 66-40 to cover 38 foreign peptide API manufacturers across China, India, and South Korea, impacting ~30% of US injectable peptide supply.
Read ArticlePharmaBlock Sciences opens a 600L SPPS GMP pilot plant at its Zhejiang site, supporting scale-up from R&D to pilot-scale peptide API production.
Read ArticleAn estimated $3.1B in reshoring-related peptide manufacturing investment has been announced since January 2025, driven by the BIOSECURE Act and supply chain risk.
Read ArticleAnalysis of FDA warning letters issued to peptide suppliers from 2024 to 2025 reveals consistent patterns in unapproved drug marketing, GMP violations, and the limits of "research use only" disclaimers.
Read ArticleThe EMA’s first-ever dedicated Guideline on the Development and Manufacture of Synthetic Peptides took effect June 1, 2026. Here is what the document actually requires.
Read ArticleReal financial data and capacity details for the three biggest peptide CDMOs, plus market sizing and what the capacity crunch means for buyers.
Read ArticleFDA and EMA have issued updated GMP guidance for peptide drug manufacturers, with new requirements for process validation, impurity control, and quality systems.
Read ArticleWhat it means when a peptide facility is EDQM-approved: how Certificate of Suitability (CEP) applications work, which peptide APIs hold them, and how buyers should verify one.
Read Article